Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8758090 | European Journal of Internal Medicine | 2018 | 7 Pages |
Abstract
Carbapenem-sparing regimens (e.g. piperacillin-tazobactam alone or with an aminoglycoside) could be empirically safely used in elderly patients at high risk of ESBL-EB BSI and for definitive treatment of ascertained cases if the primary site is the urinary tract, leaving early carbapenem use for cases at higher risk of death, such as those with pneumonia.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Simone Meini, Raffaele Laureano, Carlo Tascini, Fabio Arena, Lucia Fani, Anna Frullini, Maria Teresa Passaleva, Anna Teresa Roberts, Dario Mannini, Francesco Sbrana, Andrea Ripoli, Gian Maria Rossolini,